Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Camidanlumab tesirine for R/R non-Hodgkin or Hodgkin lymphomas

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the Phase I study (NCT02432235) evaluating the safety and efficacy of camidanlumab tesirine (Cami-T or ADCT-301), an antibody-drug conjugate, in patients with relapsed/refractory non-Hodgkin or Hodgkin lymphomas. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Collins discusses the promising results from this study, before stressing the need to find the optimal dose; maximizing efficacy, but minimizing the toxicity.